Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse. According to the American Heart Association (AHA), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer. For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size.
Into that persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw. What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity.
The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the condition. The company’s recent commercial and regulatory milestones give additional shape to the investment thesis. More details can be found in the company’s newsroom at https://ibn.fm/CDIO.
Cardio Diagnostics’ integrated approach combines epigenetic biomarkers with AI-driven algorithms to identify patients at risk for coronary heart disease, even before symptoms appear. This method addresses a critical gap in current diagnostics, which often miss early-stage disease or rely on invasive procedures. The company’s technology has the potential to reduce healthcare costs by enabling earlier intervention and preventing costly hospitalizations. As the AHA projects, the economic burden of cardiovascular disease will only escalate, making innovative diagnostic solutions like those from Cardio Diagnostics increasingly important.
InvestorWire, a specialized communications platform, covers the latest news and updates relating to CDIO. For more information about InvestorWire and its parent company IBN, visit https://www.InvestorWire.com. The platform provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. By cutting through the overload of information in today’s market, InvestorWire brings its clients unparalleled recognition and brand awareness.
